Assero and S-Cubed create A3 Informatics
The U.K.-based consultancy firm Assero and the European CRO S-Cubed have joined forces to establish A3 Informatics, a joint venture that is designed to help companies working with CDISC (Clinical Data Interchange Standards Consortium) standards and assist with data management. The plan is to showcase the business at the PhUSE Annual Conference in Edinburgh, Scotland on October 8, 2017.
“I am proud to be bringing a set of technologies to the industry that it has long needed,” noted Dave Iberson-Hurst, who has advocated the use of standards for the last 15 years and has helped design and develop A3 Informatics’ “Tools: The Glandon Suite.” “I am looking forward to introducing A3 Informatics to the wider community and changing the way that we work with data.”
Iberson-Hurst has worked with S-Cubed’s managing director Scott McGregor and partner Niels Both for more than a decade. S-cubed is a European company based in Denmark and the U.K. with full-service CRO capabilities, specializing in biometrics, CDISC standards (implementation and conversion), regulatory affairs, business intelligence, quality assurance, and project management.
Both’s experience of working with CDISC standards and awareness of the issues that companies faced with implementation will be vital for A3 Informatics, according to a joint statement from both companies.
“Dave and I have worked together for many years and it is clear that there has to be another way of working with the data in clinical trials,” he said. “A3 Informatics offers solutions that can drive the industry away from endless mapping and conversions and lead to a more efficient and accurate way of working.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
